Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : °øÁö»çÇ×
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_¼¼°è ¾à±¹µéÀÇ °¨¿°¼º Áúȯ °¨½Ã ¹× ´ëÀÀ »ç·Ê ¼Ò°³ 1Æí
³»   ¿ë
ÃÖ±Ù Áß±¹ ¿ìÇѽø¦ Áß½ÉÀ¸·Î ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ È®»ê¼¼°¡ »¡¶óÁö¸é¼­ Áß±¹¿¡¼­´Â ´©Àû »ç¸ÁÀÚ°¡ 490¸í, ´©Àû È®ÁøÀÚ ¼ö´Â 2¸¸ 4õ ¸íÀ» ³Ñ¾î¼­°í ÀÖ´Ù. ¿ì¸®³ª¶ó¿¡¼­µµ ´©Àû È®ÁøÀÚ°¡ 19¸íÀ̰í, 174¸í¿¡ ´ëÇØ¼­´Â °ü·Ã °Ë»ç°¡ ÁøÇà ÁßÀÌ´Ù(2020³â 2¿ù 5ÀÏ ±âÁØ). 2002³â »ç½º, 2009³â ½ÅÁ¾Çà·ç, 2012³â ¸Þ¸£½º¿¡ À̾î 2019³â ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º(¿ìÇÑÆó·Å)±îÁö ¡®°ú°Å Çü¡¯ÀÌ ¾Æ´Ñ ¡®ÇöÀç ÁøÇàÇü¡¯ À¸·Î Áö±¸ÃÌ °÷°÷¿¡¼­ Áö¼ÓÀûÀ¸·Î ´Ù¾çÇÑ Á¾·ùÀÇ Àü ¿°º´À̠â±ÈÇϰí ÀÖ´Ù°í Çصµ °ú¾ðÀÌ ¾Æ´Ñ »óȲÀ̶ó ÇϰڴÙ. ÀÌó·³ °¨¿°¼º ÁúȯÀÇ È®»ê ¹æÁö¸¦ À§ÇÑ ¹ü±¹°¡Àû Â÷¿øÀÇ È¿°úÀûÀÌ°í ½Å¼ÓÇÑ ´ëÀÀÃ¥ ¸¶·ÃÀÌ Àý½ÇÇÑ ½ÃÁ¡¿¡ ¾à±¹ÀÇ ¶Ù¾î³­ Á¢±Ù¼ºÀ» °í·ÁÇØ, ¼¼°è¾à»ç¿¬¸Í(International Pharmaceutical Federation; FIP)¿¡¼­´Â 2014³â ¼­¾ÆÇÁ¸®Ä«¸¦ Áß½ÉÀ¸·Î È®»êµÆ´ø ¡¯¿¡º¼¶ó¡® ¹ÙÀÌ·¯½º À¯Çà ´ç½Ã °¨¿°º´ ¹ß»ý°ú °ü·ÃÇØ ¼öÇàÇØ¾ß ÇÒ ¾à»ç ¹× Áö¿ª¾à±¹ÀÇ ¿ªÇÒ°ú °ü·ÃÇÑ °¡À̵å¶óÀÎ(Ebola Virus Disease: Information and Guidelines for Pharmacists and the Pharmacy Workforce)À» ¹ßÇ¥ÇÑ ¹Ù ÀÖ´Ù. º» °í¿¡¼­´Â ½ÅÁ¾Àü¿°¼ºÀ̶ó´Â À¯»ç¼ºÀ» °í·ÁÇÏ¿© ÀÌ¿¡ ´ëÇØ ¿ì¼±ÀûÀ¸·Î »ìÆìº¸°í, ÀÌÈÄ¿¡´Â FIP¿¡¼­´Â Á¶¸¸°£ »õ·Ó°Ô ¹ßÇ¥ÇÒ ¿¹Á¤ÀΠ¡®½ÅÁ¾ Äڷγª ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ¾à±¹ÀÇ Æ÷°ýÀû ´ëÀÀÁöħ¡¯µéÀ» ¼Ò°³ÇϰíÀÚ ÇÑ´Ù. ¶ÇÇÑ, Áֿ䠿ܱ¹ÀÇ Àü¿°º´ °¨½Ã ¹× ´ëÀÀ Ã¼°è¿¡¼­ÀÇ ¾à±¹ÀÇ ¿ªÇÒ°ú ³ë·Âµé¿¡ ´ëÇØ¼­µµ Â÷·Ê ·Î »ìÆìº¼ ¿¹Á¤ÀÌ´Ù. [ÆíÁýÀÚ ÁÖ]



Áö¿ª¾à±¹ÀǠåÀÓ°ú ¿ªÇÒ 
Áö¿ª¾à±¹Àº º¸°ÇÀÇ·á½Ã½ºÅÛÀÇ ÃÖÀü¹æ¿¡¼­ ÀǽÉȯÀÚ ¶Ç´Â À¯Áõ»óÀÚ µéÀÌ °Ç°­ °ü·Ã »ó´ãÀ̳ª ´Ü¼øÇÑ Á¤º¸ ¶Ç´Â ¾à¹°°ú °ü·ÃµÈ ½Å·Ú¼º Àִ Á¶¾ðÀ» ¾ò±â À§ÇØ °¡Àå ¸ÕÀú Á¢±ÙÇϴ ½Ã¼³ÀÌ´Ù. 
µû¶ó¼­ Áö¿ª¾à±¹Àº °¨¿°¼º Áúȯ¿¡ ´ëÇØ ´ÙÀ½°ú °°Àº Ã¥ÀÓÀ» Áö´Ï°Ô µÈ´Ù: 
- °¨¿°¼º Áúȯ °ü·Ã Á¤º¸Á¦°ø ¹× »ó´ã 
- Á¶»ç ´ë»ó À¯Áõ»óÀÚ ¹× ÀǽÉȯÀÚ¿¡ ´ëÇÑ °ü·Ã º¸°ÇÀÇ·á±â°üÀ¸·ÎÀÇ ÀÇ·Ú 
- °¨¿°¿¹¹æ È°µ¿ 
- °¨¿°ÀÇ È®»ê ÅëÁ¦ ÃËÁø 

¿¹¹æ(Prevention) 
¾à»ç¿Í ¾à±¹Àº ¾Æ·¡¿Í °°ÀÌ °¨¿°¼º ÁúȯÀÇ ¿¹¹æ¿¡ ÁÖ¿ä ¿ªÇÒÀ» ¼öÇà ÇÒ ¼ö ÀÖ´Ù. 
- Áúº´ÀÇ ¿øÀÎ, °¨¿° °æ·Î, ±×¸®°í ÀÌÈÄ È®»êÀ» ¸·À» ¼ö Àִ ¹æ¹ý¿¡ ´ëÇÑ Á¤È®ÇÑ ÀÌÇØ 
- º¸°Ç´ç±¹ÀÌ Á¦½ÃÇϰí Àִ ´ëÀÀ¹æ¾È¿¡ ´ëÇÑ ¼÷Áö(°¡Àå °¡±î¿î °Å¸® ¿¡ È¯ÀÚ¸¦ ÀÇ·ÚÇØÁÙ ¼ö Àִ °ÅÁ¡ÀÇ·á±â°ü Á¤º¸ Æ÷ÇÔ) 
- Áö¿ª»çȸ¿¡ ´ëÇÑ Á¤º¸Á¦°ø, Á¶¾ð, ±×¸®°í ±³À° 
- ÀûÀýÇÑ ÀǾà¿ëǰÀÇ °ø±Þ 
- ¹ÙÀÌ·¯½º °¨¿°ÀÌ ÀǽɵǴ Áõ»óÀ» º¸À̴ ȯÀÚ°¡ ÀûÀýÇÑ ¼³ºñ¸¦ °® Ãá ÀÇ·á½Ã¼³À» ¹æ¹®ÇÒ ¼ö ÀÖµµ·Ï ¾È³»ÇÔ. ÃæºÐÇÑ ÀÇ·á½Ã¼³À» °®Ãß Áö ¾ÊÀº ½Ã¼³·ÎÀÇ ÀǷڴ º¸°ÇÀÇ·áÀü¹®°¡¿Í È¯ÀÚ ¸ðµÎ¸¦ À§Çè¿¡ ºü Æ®¸± ¼ö ÀÖÀ½. 

ȯÀÚ ½ºÅ©¸®´×(Screening) 
°¨¿°ÀÌ ÀǽɵǴ ȯÀÚ°¡ ÀÖ´Ù°í ÆÇ´ÜµÉ °æ¿ì, ½Å¼ÓÇϰí Á¤È®ÇϰԠÀÇ ½ÉȯÀڷΠºÐ·ùÇϴ °úÁ¤À» °ÅÃÄ ÀûÀýÇÑ º¸°ÇÀÇ·á½Ã¼³À̳ª º¸°Ç´ç±¹¿¡ ÀÇ·ÚÁ¶Ä¡Çϴ °ÍÀº º¸°ÇÀÇ·á½Ã½ºÅÛ¿¡¼­ ¾à±¹ÀÌ ¼öÇàÇØ¾ß ÇÒ Áß¿äÇÑ ¿ª ÇÒÀÌ´Ù. ±× ¿¹·Î, ¿¡º¼¶ó ¹ÙÀÌ·¯½º ÀǽÉȯÀÚ ºÐ·ù¸¦ ÅëÇÑ ½Å°í ¹× ´ëÀÀ ¿¡ ´ëÇØ FIP´Â ¾Æ·¡¿Í °°Àº ÁöħÀ» Á¦½ÃÇÑ ¹Ù ÀÖ´Ù. 
¿¡º¼¶ó ¹ÙÀÌ·¯½ºÀÇ ÃʱâÁõ »óÀº Æ¯À̼ºÀÌ ¾ø°í ÀϹÝÀûÀΠµ¶°¨ Áõ»ó°ú À¯»çÇϹǷÎ, È¯ÀÚ ¿¡°Ô 3ÁÖ À̳» ¿¡º¼¶ó À§ÇèÁö ¿ªÀ» ¹æ¹®ÇÑ °æÇèÀÌ Àְųª, È®ÁøÀÚ³ª ÀǽÉȯÀÚ¿Í ¹ÐÁ¢ÇÏ °Ô Á¢ÃËÇÑ °æÇè À¯¹«, ÀÏÁ¤Á¤ µµÀÇ ¹ß¿­ ¿©ºÎ µîÀ» È®ÀÎÇÔÀ¸ ·Î½á ÀǽÉȯÀÚ·ÎÀÇ ºÐ·ù¸¦ ¸í È®ÇϰԠÇÒ ¼ö ÀÖ´Ù. 

ÀÇ·Ú(Referral) 
¿ì¼± °¨¿°ÀÌ ÀǽɵǴ °æ¿ì È¯ÀÚ°¡ ÀûÇÕÇÑ º¸°ÇÀÇ·á½Ã¼³ À» Ã£¾Æ Áï°¢ÀûÀΠÁ¶Ä¡¸¦ ¹Þ À» ¼ö ÀÖµµ·Ï Áö¿øÇؾߠÇÑ´Ù. WHO´Â ¹ÙÀÌ·¯½º °¨¿° Áõ»ó À» º¸À̴ ȯÀÚ¸¦ °¡Á¤À̳ª Áö¿ª»çȸ ³»¿¡¼­ µ¹º¸´Â °ÍÀ» ±ÇÀåÇÏÁö ¾Ê ´Â´Ù. 
Àǽɻç·Ê¸¦ ÀÇ·ÚÇϴ ´Ü°è¿¡¼­ ±¹°¡, Áö¿ª ¶Ç´Â Áö¿ªº¸°Ç¼ÒÀÇ Àç³­ ´ëºñ ´ëÀÀÃ¥À̠Ȱ¿ëµÉ ¼ö ÀÖÀ¸¸ç ¾à±¹Àº º¸°Ç ´ç±¹°ú ÇùÁ¶ÇØ Àç³­ ´ëºñ Çൿ ¿ä·ÉÀ» ½ÃÇàÇϴ °úÁ¤À» ¼÷ÁöÇϰí ÀÖ¾î¾ß ÇÑ´Ù. 
- ÀÏÂ÷ÀûÀ¸·Î ÀǽÉȯÀÚ¸¦ ºÐ¸®µÈ °ø°£¿¡ °Ý¸®Çϰí, 
- ÀûÀýÇÑ ÀÀ±Þ¼­ºñ½º¸¦ À§ÇØ º¸°Ç´ç±¹¿¡ Áï°¢ÀûÀΠ¿¬¶ôÀ» ÃëÇÔÀ¸·Î½á 
- ÈƷõȠÀü¹®°¡µéÀÌ ÀǽÉȯÀÚ¸¦ ÁöÁ¤µÈ º¸°ÇÀÇ·á½Ã¼³·Î À̼ÛÇÒ ¼ö ÀÖµµ·Ï ÇÔ. 
FIPÀÇ Áöħ¿¡¼­ ºÐ¸®µÈ °ø°£Àº È¯ÀÚÀÇ ´ë±â Áß Ãß°¡ °¨¿°°æ·Î ¹ß»ý ÀÇ ¿ì·Á¸¦ ¸·±â À§ÇÑ °ø°£À¸·Î, È­Àå½Ç ¹× ÃÖ¼ÒÇÑÀÇ °¡±¸ ¶Ç´Â ¹°Ç°À» °®Ãßµµ·Ï Çϰí ÀÖ´Ù. 
ÀǽÉȯÀÚ°¡ ÀÇ·á½Ã¼³·Î À̼۵ȠÈÄ, È¯ÀÚ°¡ ¾à±¹ ³»¿¡¼­ ¸Ó¹«¸¥ °ø°£ Àº ÀǽÉȯÀÚ°¡ ¡®ÀǽÉÇØÁ¦¡¯ Áø´ÜÀ» ¹ÞÀ» ¶§±îÁö Àý´ë·Î »ç¿ëµÇ¼­´Â ¾È µÈ ´Ù. ¶ÇÇÑ ¡®È®ÁøÀÚ¡¯·Î ÆÇÁ¤µÉ °æ¿ì, È¯ÀÚ°¡ ¸Ó¹°·¶´ø °ø°£¿¡ ´ëÇØ¼­´Â º¸ °Ç´ç±¹ÀÇ ÇÁ·ÎÅäÄÝ¿¡ µû¶ó È¯°æ¼Òµ¶ ÀýÂ÷¸¦ °ÅÃľߠÇÑ´Ù. 

°¨¿°ÀÇ È®»ê ÅëÁ¦: ¼Õ¼¼Á¤Á¦ 
¾à±¹Àº ¾ËÄÚ¿ÃÀÌ µé¾î°£ ¼Õ¼¼Á¤Á¦¸¦ ¹Ýµå½Ã ±¸ºñÇØ¾ß Çϸç, ÀÚÁÖ ¼ÕÀ» ¾Ä´Â °Í¿¡ ´ëÇÑ Á߿伺À» È¯Àڵ鿡°Ô °­Á¶ÇؾߠÇÑ´Ù. ¼ÕÀǠû°á Àº ¹ÙÀÌ·¯½ºÀÇ ÀüÆÄ¸¦ ¸·±â À§ÇØ ÇʼöÀûÀ̸ç, WHO¿¡¼­ ±Ç°íÇÑ ¹æ¹ý ¿¡ µû¶ó ºñ´©¸¦ È帣´Â ¹°°ú ÇÔ²² »ç¿ëÇϰųª ¾ËÄÚ¿ÃÀÌ µé¾î°£ ¼Õ¼¼ Á¤Á¦¸¦ »ç¿ëÇØ¾ß ÇÑ´Ù. WHO¿¡ µû¸£¸é ¼Õû°áÁ¦ÀÇ ¾ËÄڿàÇÔÀ¯·®Àº 80%(ethanol), ¶Ç´Â 75%(isopropyl alcohol)°¡ ÀûÇÕÇÏ´Ù. 

¾à»ç¿Í ¾à±¹ Á¾¾÷¿ø 
ºñ¾à»ç ÀηÂÀ» Æ÷ÇÔÇÑ ¾à±¹ ³» Á÷¿ø ¸ðµÎ°¡ °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ´ëÀÀ ÁöħÀ» Á¤È®ÇϰԠ¼÷ÁöÇϴ °ÍÀÌ Áß¿äÇÏÁö¸¸, È¯ÀÚÀÇ À§Ç輺 Æò°¡´Â ¾à »ç¿¡ ÀÇÇØ¼­ ¼öÇàµÅ¾ß ÇÑ´Ù. ¶ÇÇÑ, ¾à»ç´Â ¹ÙÀÌ·¯½º °¨¿° ÀǽÉȯÀÚ¸¦ °ü·Ã ÀÇ·á±â°üÀ̳ª Á¤ºÎ±â°ü¿¡ Áï°¢ ÀÇ·ÚÇÒ ¼ö ÀÖ¾î¾ß ÇÑ´Ù. 

¡Ø FIP´Â Áö³­´Þ(1¿ù) 31ÀÏ¿¡ ½ÅÁ¾ Äڷγª °ü·Ã ¾à±¹ Áöħ ¹®¼­¸¦ °³¹ß ÁßÀ̸ç, ÃÖ´ëÇÑ À̸¥ ½ÃÀÏ ³»·Î È¸¿ø±¹µé¿¡ Á¦°øÇÒ °ÍÀÓÀ» °ø½Ä SNS°èÁ¤À» ÅëÇØ °øÁöÇß´Ù. 
<´ÙÀ½È£¿¡ °è¼Ó> 

2¿ù 10ÀÏ¿¡ °ÔÀçµÉ ¿¹Á¤À̾ú´ø ¡®Non-communicable disease, NCD) ºñ°¨¿°¼º ¸¸¼ºÁú È¯¿¡ ´ëÀÀÇϱâ À§ÇÑ Á¶¾ð¡¯ 2ÆíÀº ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º È®»ê ¿©ÆÄ·Î ±â»çÈ­ ÀÏÁ¤ÀÌ ÀϺΠº¯µ¿µÇ¾úÀ½À» ¾Ë·Áµå¸³´Ï´Ù.


https://www.e-kippa.org:444/bbs/common/write.asp?table=bbs_notice&category=1

 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
168 û³â¾à»ç¿Í ¾à´ë»ýÀ» À§ÇÑ Ä¿¸®¾î °³¹ß °¡À̵åºÏ ÃÖÀ±Á¤ 2022-02-14 2661
167 2020³â ±âºÎ±Ý ¸ðÁý ¹× ÁöÃâ ¸í¼¼¼­ ÀÌÁö¿¬ 2021-05-10 1579
166 [ȯÀÚ¾ÈÀü º¸°íÇнÀ ½Ã½ºÅÛ] '¾à±¹ ¾àÁ¦¾÷¹« °ü¸®Áöħ ¾È³»' °Ô½Ã ±èÁøÀÌ 2020-06-25 3709
165 2021 ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¿¬±¸¿ø ä¿ë °ø°í °ü¸®ÀÚ 2020-03-12 6842
164 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_Á¶±â´ëÀÀü°è¿¡ ÃÖÀûÈ­µÈ ¡®¾à±¹±â¹Ý °¨½Ã ½Ã½ºÅÛ¡¯ ±è¼±Èñ 2020-02-26 3637
163 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_Äڷγª19 ´ëÀÀ FIP ½Å±Ô °¡À̵å¶óÀÎ ±è¼±Èñ 2020-02-26 3218
162 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_¼¼°è ¾à±¹µéÀÇ °¨¿°¼º Áúȯ °¨½Ã ¹× ´ëÀÀ »ç·Ê ¼Ò°³ 1Æí ±è¼±Èñ 2020-02-12 2105
161 "¾à·á»ç¾÷ ³Ñ¾î Áö¿ª Á᫐ ¾à±¹ °Ç°­Çãºê ¿ªÇÒ Èû¾µ °Í" ±è¼±Èñ 2020-01-30 1715
160 "¾à±¹ '°Ç°­ÁõÁø Çãºê' ¹æÇâÀ¸·Î °¡¾ß"...·¹Áö½ºÆ®¸® ±¸Ãà º»°ÝÈ­ ±è¼±Èñ 2020-01-30 1516
159 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]¿µ±¹ ¾à±¹, °Ç°­ »ýȰ ¼¾ÅÍ·Î ¹ßµ¸¿ò ±è¼±Èñ 2020-01-30 1710
158 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]È£ÁÖ, ¹æ¹® ¾à·á µµÀÔÇØ ¾à¹° ¿ä¹ý ÇýÅà ±Ø´ëÈ­ ±è¼±Èñ 2020-01-30 1421
157 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]ÀϺ», ¡®´Ü°ñ¾à»ç-ÀçÅù湮¿Ï·á¡¯ È£Æò ¼Ó Ȱ¼ºÈ­ ±è¼±Èñ 2020-01-30 1511
156 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]±¹³»¿Ü »ç·Ê°íÂûÀ» ÅëÇÑ Ä¿¹Â´ÏƼ Äɾ¼­ÀÇ Áö¿ª¾à±¹ ¹× ¾à»ç ¿ªÇÒ Å½»ö 1 ±è¼±Èñ 2020-01-30 1412
155 [±â»ç]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, ÆÐ³Î¾à±¹ ¸ðÁý Ȱµ¿ Àü°³ ±è¼±Èñ 2019-11-13 1573
154 [±â»ç]¾à±¹¸¸ÀÇ Ã¼°èÀû Á¤Ã¥¼ö¸³À§ÇÑ ¾à±¹DB ±¸Ãà 'ù¹ß' ±è¼±Èñ 2019-11-13 1479

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»